导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 10.14% | 710/4773 |
| 近一周 | -2.41% | 2096/5462 |
| 近一月 | -4.77% | 2724/5421 |
| 近一季 | -8.98% | 3051/5209 |
| 近半年 | -0.04% | 1220/4920 |
| 近一年 | 17.00% | 555/4366 |
| 近两年 | 90.64% | 680/2954 |
| 近三年 | 49.65% | 543/2253 |
| 成立以来 | 163.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.38% 525/4961 |
24.84% 1051/5312 |
- - |
- - |
| 2025 | 38.78% 859/4813 |
4.02% 1004/3635 |
4.44% 761/4076 |
23.03% 1590/4524 |
3.83% 612/4813 |
| 2024 | 3.97% 1901/3463 |
-2.64% 1397/2808 |
-4.02% 1456/3014 |
12.00% 2435/3129 |
-0.65% 1491/3463 |
| 2023 | -6.16% 819/2656 |
8.13% 491/2280 |
-3.73% 881/2385 |
-5.29% 1303/2515 |
-4.81% 1183/2655 |
| 2022 | -10.58% 210/2207 |
-11.68% 539/1919 |
3.32% 1171/2016 |
-4.17% 47/2113 |
2.25% 1002/2208 |
| 2021 | 22.82% 136/1822 |
1.06% 264/1255 |
11.14% 397/1330 |
7.45% 187/1466 |
1.76% 806/1822 |
| 2020 | 33.63% 452/1250 |
-3.01% 285/1028 |
18.92% 317/1067 |
13.00% 349/1164 |
2.53% 983/1184 |
| 2019 | - - |
- - |
- - |
6.87% 112/850 |
10.47% 129/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 万家中证500指数增强A VS. 长安沪深300非周期A(740101) |